Opinion|Videos|December 16, 2025
Insurance Coverage and Patient Education
Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
- From your experience, what has insurance coverage been like for the pharmacotherapies used to treat desmoid tumors? Why might a step through with tyrosine kinase inhibitors before nirogacestat not be beneficial for patients? How do you educate patients about desmoid tumors and are there any resources that you find useful?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
5